135 completed, 30 terminated, 10 active not recruiting, 7 unknown. 192 Phase 1, 43 Phase 2.
Follow Oligodendroglioma: new trials by email Literature Review of Oligodendroglioma trials Research Report on Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) SRN-101 - Recurrent High Grade Gliomas, Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | Siren Biotechnology | 40 | 2026-12-01 | 2026-10-28 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma exHSC, Nivolumab, Resection or biopsy - Recurrent High-grade Glioma, Grade III Astrocytoma | Phase 1 | Active not recruiting | University of Florida | 12 | 2025-07-25 | 2026-09-23 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401) 5-Aminolevulinic acid Hydrochloride (Gliolan®), CV01 - Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO) | Phase 1 | Completed | Universität Münster | 16 | 2025-01-27 | 2026-02-27 |
| ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT - Recurrent Oligodendroglioma, Progressive Oligodendroglioma | Phase 1 | Active not recruiting | University of Florida | 12 | 2024-09-19 | 2026-11-13 |
| A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma PCI 24781, Temozolomide - Recurrent High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Recruiting | University of Nebraska | 24 | 2023-06-26 | 2026-09-14 |
| Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID - High-grade Glioma, Oligodendroglioma | Phase 1 | Active not recruiting | Oblato, Inc. | 16 | 2023-04-17 | 2024-11-29 |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma Vorasidenib, Pembrolizumab - Astrocytoma, Oligodendroglioma | Phase 1 | Active not recruiting | Institut de Recherches Internationales Servier | 60 | 2023-01-20 | 2026-03-12 |
| Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq - Recurrent High-grade Glioma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Terminated | Dawonmedax Co., Ltd. | 7 | 2022-12-05 | 2025-02-21 |
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants OKN-007 - Glioblastoma, Astrocytoma | Phase 1 / Phase 2 | Withdrawn | Oblato, Inc. | 2022-08-01 | 2022-10-07 | |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years - Medulloblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Children's Oncology Group | 35 | 2022-07-01 | 2026-06-02 |
| SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma Mirdametinib - Low-Grade Glioma, Recurrent Low-Grade Glioma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 132 | 2021-06-21 | 2026-09-11 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms ONC206 - Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Active not recruiting | Jazz Pharmaceuticals | 35 | 2020-10-26 | 2026-11-09 |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas INCB7839 - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 13 | 2020-07-27 | 2026-10-01 |
| Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg - High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2019-12-06 | 2023-10-06 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors G207 - Neoplasms, Brain, Glioblastoma Multiforme | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-12 | 2026-09-04 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Polio/Rhinovirus Recombinant (PVSRIPO) - Malignant Glioma, Anaplastic Astrocytoma | Phase 1 | Completed | Istari Oncology, Inc. | 8 | 2017-11-07 | 2024-04-08 |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 rQNestin, Cyclophosphamide, Stereotactic biopsy - Malignant Glioma of Brain, Astrocytoma | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 62 | 2017-07-18 | 2026-03-04 |
Showing 20 of 192. Sign in to see all of them.
Astrocytoma (187) · Glioblastoma (146) · Glioma (120) · Brain Neoplasms (116) · Gliosarcoma (104) · Central Nervous System Neoplasms (90) · Medulloblastoma (57) · Ependymoma (49) · Choroid Plexus Neoplasms (37) · Familial ependymoma (36) · Optic Nerve Glioma (32) · Meningioma (27) · Neuroectodermal Tumors, Primitive (26) · Glioma, Subependymal (19)
Neoplasms by Histologic Type (191) · Neoplasms, Glandular and Epithelial (191) · Neoplasms, Nerve Tissue (191) · Neuroectodermal Tumors (190) · Neoplasms, Germ Cell and Embryonal (188) · Neoplasms, Neuroepithelial (184) · Neoplasms (182) · Neoplasms by Site (160) · Nervous System Diseases (160) · Nervous System Neoplasms (160) · Central Nervous System Diseases (151) · Brain Diseases (148) · Glioma (72) · Central Nervous System Neoplasms (71) · Neuroectodermal Tumors, Primitive (38)
Temozolomide (31) · Carboplatin (10) · Carmustine (9) · Filgrastim (9) · Irinotecan (9) · Erlotinib Hydrochloride (7) · Surgical Procedures, Operative (7) · Bevacizumab (6) · Flucytosine (6) · O(6)-benzylguanine (6) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (5) · Imatinib Mesylate (5) · Radiotherapy (5) · Vorinostat (5) · temsirolimus (5)
National Cancer Institute (NCI) (38) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (13) · Duke University (12) · Pediatric Brain Tumor Consortium (12) · City of Hope Medical Center (11) · National Institutes of Health Clinical Center (CC) (7) · Jonsson Comprehensive Cancer Center (6) · New Approaches to Brain Tumor Therapy Consortium (5) · Children's Oncology Group (4) · M.D. Anderson Cancer Center (4) · Tocagen Inc. (4) · Case Comprehensive Cancer Center (3) · Mayo Clinic (3) · Memorial Sloan Kettering Cancer Center (3) · Northwestern University (3)
United States (181) · Canada (10) · Australia (3) · Germany (2) · Switzerland (2) · Belgium (1) · France (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Darell D. Bigner, MD, PhD (6) · Asha Das, MD (4) · Howard A. Fine, MD (4) · Jana Portnow (4) · Stuart A. Grossman, MD (4) · David A. Reardon, MD (3) · Henry S. Friedman, MD (3) · Jana Portnow, MD (3) · Jeffrey Raizer, MD (3) · Michael Prados, MD (3) · Annick Desjardins, MD (2) · Edward A. Neuwelt, MD (2) · Edward Pan, MD (2) · Elizabeth Fox, MD (2) · Evanthia Galanis (2)
PMID 23377664, PMID 11410496, PMID 12721262, PMID 14670747, PMID 14769140, PMID 15292713, PMID 16012795, PMID 16061868, PMID 16192602, PMID 16234526, PMID 16533779, PMID 16533878, PMID 16914576, PMID 16914578, PMID 17264335, PMID 17470857, PMID 17634493, PMID 17694310, PMID 17941066, PMID 18048828, PMID 18056189, PMID 18056194, PMID 18094423, PMID 18281544, PMID 18359865, PMID 18470481, PMID 18477765, PMID 19065567, PMID 19075272, PMID 19248046, PMID 19289491, PMID 19430790, PMID 19768386, PMID 20044751, PMID 20049936, PMID 20460632, PMID 21377994, PMID 21547395, PMID 21764821, PMID 21850464, PMID 22291006, PMID 22323663, PMID 23349317, PMID 23380277, PMID 23388559, PMID 23554030, PMID 24470557, PMID 24786603, PMID 28371832, PMID 28870792
U01CA081457 (13), P30CA033572 (7), U01CA062399 (4), U01CA137443 (4), U01CA062475 (3), U01CA097452 (3), P30CA008748 (2), P30CA015083 (2), P30CA016056 (2), P30CA043703 (2), U01CA069856 (2), U10CA025224 (2), UM1CA081457 (2), UM1CA137443 (2), 2023 (1)